TABLE 5.
Comparison of Relevant Endpoints for Acrolein and CRO
| Endpoint | Acrolein | CRO | Relative potency |
|---|---|---|---|
| RD50 | 6 ppm | 23.2 ppm | 3.87 |
| Male Fisher-344 rats | |||
| Babiuk, Steinhagen, and Barrow (1985) | |||
| RD50 | 1.41 ppm | 4.88 ppm | 3.46 |
| Male B6C3F1 mice | |||
| Steinhagen and Barrow (1984) | |||
| RD50 | 1.03 ppm | 3.53 ppm | 3.43 |
| Male Swiss-Webster mice | |||
| Steinhagen and Barrow (1984) | |||
| LD50 | 50 mg/kg | 140 mg/kg | 2.80 |
| Rat (subcutaneous injection) | |||
| LD50 | 30 mg/kg | 160 mg/kg | 5.33 |
| Mouse (subcutaneous injection) | |||
| IC50 values for viability (in vitro) in mouse lymphocytes | 2.70 × 10−5 (molar concentrations) | 4.26 × 10−5 (molar concentrations) | 1.58 |
| Poirier et al. (2002). | |||
| Cell viability (in vitro) in cultured normal human lung fibroblasts | 25 | 91 | 3.64 |
| Moretto et al. (2009) |